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Background/aim: This study aimed to investigate the prevalence of sicca symptoms and secondary Sjögren’s syndrome (SjS) in patients
with systemic sclerosis (SSc). Also this study aimed to evaluate the expression of α-smooth muscle actin (α–SMA) in minor salivary
gland (MSG) specimens, a possible marker of fibrosis responsible for myofibroblastic transformation.
Materials and methods: Patients with SSc who were followed in Rheumatology outpatient clinic at a university hospital evaluated.
The questionnaire of sicca symptoms and classification of SjS were evaluated according to the American–European Consensus Group
(AECG) criteria. Histopathologic evaluations were done in MSG specimens investigating the presence of focal lymphocytic sialadenitis
and glandular fibrosis, also assessing the expression of α–SMA.
Results: This cross-sectional study included 102 patients with SSc [91 females (89%), mean age 52.5 ± 12 years]. In this cohort 76 (75%)
patients had sicca symptoms and 36 (35.3%) patients fulfilled the AECG criteria for SjS; all with limited form. Having SjS found to be
associated with older age and the presence of positive anti-SS-A antibodies. On histopathologic examinations, glandular fibrosis was
observed in 67 (80%) and lymphocytic sialadenitis was detected in 38 (45%) patients; but only 7 samples were positive for α–SMA.
Conclusion: This study suggested sicca symptoms were found to be very common among patients with SSc. Also secondary SjS was
detected in nearly one-third of patients with SSc; especially in limited subtype. Anti SS-A positivity and older age were detected as
predictors for SjS. Histopathologic evaluations showed significant glandular fibrosis but rare α-SMA staining in patients with SSc.
Key words: Fibrosis, scleroderma, sicca, Sjögren’s syndrome, alpha-SMA

1. Introduction
Scleroderma (SSc) is a heterogeneous systemic disorder
characterized by massive accumulation of collagen and
matrix proteins in connective tissue [1]. SSc may also
co-exist with Sjögren’s syndrome (SjS), systemic lupus
erythematosus (SLE), rheumatoid arthritis (RA) or
polymyositis (PM) at variable rates and this condition is
referred to as overlap syndrome.
SjS is a chronic autoimmune disorder that
predominantly affects exocrine glands. Essential
histological characteristic of SjS is focal lymphocytic
infiltration of salivary and lacrimal glands. The rate of
secondary SjS has been found, as 17%–19% in previous

publications while extreme rates such as 1%–90% have
also been reported among patients with SSc [2]. Sicca
symptoms such as xerostomia or xerophthalmia are also
common in patients with SSc [3]. The condition that leads
to hypofunction of exocrine tissues such as salivary glands
in SSc has been commonly linked to glandular fibrosis and
in certain studies; it has been linked to coexistence of SjS
and SSc [4]. In a previous study, subjective xerostomia was
reported in 68% of the patients with SSc and histological
analysis of minor salivary gland (MSG) biopsies revealed
‘fibrosis’ in 55% of these patients [4].
The main characteristic of the SSc pathogenesis is
pathological fibrosis: excessive deposition of extracellular
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matrix (ECM) induced by activated fibroblasts [5]. During
the tissue repair process, fibroblasts and other progenitor
cells differentiate into myofibroblasts in response to
extracellular signals that is followed by the induction of
collagen synthesis, the synthesis of other ECM proteins,
connective tissue adhesion and contraction, the release
of growth factors. Under physiological conditions,
the repair program is a self-limited, strictly controlled
process. However, pathological fibrosis is characterized
by continuous and increased fibroblast activation, which
results in excessive ECM deposition and remodeling.
Cells affected by SSc during the earlier stages include
endothelial cells, pericytes, vascular smooth muscle cells
and immune cells in the perivascular spaces. Among these
cells, only endothelial cells are mesenchymal cells subject
to apoptosis, however pericytes and smooth muscle cells
rapidly proliferate [6]. Pericytes have the potential to
differentiate into vascular smooth muscle cells, fibroblasts
and myofibroblasts [specialized contractile cells able to
secrete α-smooth muscle actin (α-SMA) and fibronectin
ED-A variant] and may affect endothelial cell proliferation.
Experimental studies indicate that myofibroblasts may play
a central role in the development of fibrosis by expressing
α-SMA in patients with SSc [7].
Therefore, this study purposed to determine the
prevalence of sicca symptoms in patients with SSc, also to
determine the patients meeting the classification criteria
of secondary Sjögren’s syndrome, based on the AmericanEuropean Consensus Group (AECG) Criteria for SjS [8].
Then, this study aimed to assess ‘α–SMA’ expression in
MSG specimens in this patient group with SSc and SjS, as
an indicator of myofibroblastic transformation, in order to
investigate the contribution of this process to the fibrosis.
2. Materials and methods
This cross-sectional study included 102 patients with SSc
who were diagnosed and followed-up in the Rheumatology
outpatient clinic at Dokuz Eylül University Medical
Faculty (İzmir, Turkey). All the patients with SSc met the
1980 American College of Rheumatology criteria for SSc
or the classification of early SSc [9,10].
The patients with SSc were consecutively selected.
Patients were excluded from the study if they had prior
therapy of head and neck irradiation, hepatitis C virus
(HCV) infection, adult immune-deficiency syndrome
(AIDS), lymphoma, sarcoidosis, immunoglobulin-G4
related disorders, graft-versus-host disease (GVHD), and
a history of anticholinergic medication use within 4 halflives of the agent prior to enrollment.
Basic demographics, clinical and laboratory data
obtained from each patient were recorded on a standard
form. The physical findings, previous medications, the
period of disease and symptoms were all recorded.
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Complete blood count (CBC), the serum renal and
liver function tests, serum albumin, globulin, protein,
creatine kinase (CK) levels, serum lactate dehydrogenase
(LDH), urinalysis, viral serology assessments for HIV and
HCV, serum C-reactive protein (CRP), and erythrocyte
sedimentation rate (ESR) assessments were all recorded.
Immunological assessments with antinuclear antibody
(ANA), Rheumatoid factor (RF), antiextractable nuclear
antigen (anti-ENA) screen (including anti-SS-A, antiSS-B, anti-U1-RNP, anti-Jo-1, anti-Sm, anti-Scl 70)
were all evaluated. ANA were assessed with immune
fluorescein assay; measurement the titer of > 1/160 was
accepted positive in the study. Anti ENA screen were
assessed with immunoblotting. RF was evaluated with
immunoturbidimetric determination method. The level of
serum RF > 14 mg/dL was accepted as positive.
The diagnosis of ILD in patients with SSc is based on
the presence of the characteristic chest high-resolution
computed tomography (HRCT) features of ILD and
exclusion of other etiologies of pulmonary parenchymal
disease. SSc-associated PAH is defined as a mean
pulmonary artery pressure (PAP) greater than 20 mmHg
in right heart catheterization, a wedge pressure less than or
equal to 15 mmHg, and a peripheral pulmonary vascular
resistance (PVR) ≥3 Wood units in patients with SSc.
The presence of subjective dry eye (xerophthalmia) and
dry mouth (xerostomia) symptoms was investigated in all
patients as defined in the AECG Classification Criteria
for SjS [8]. For patients whose responses were affirmative,
the intensity of dry eye and dry mouth symptoms were
measured using a 0 to 10 Visual Analogue Scale (VAS).
All subjects underwent the Schirmer 1 test, as an
objective diagnostic test for dry eye. The Schirmer 1 test
results were considered positive if the wetness of a filter
paper measured ≤ 5 mm [11]. Subjects also underwent the
unstimulated whole salivary flow test (UWSF), one of the
objective indicators of dry mouth. UWSF was performed
after 2 h of fasting. A falcon tube was used as a graduated
container to accumulate the saliva and a saliva flow rate of
≤ 1.5 ml/15 min was interpreted as abnormal [12].
A MSG biopsy was performed based on either (Figure
1):
· The presence of subjective sicca symptoms according
to the AECG criteria set,
· An abnormal Schirmer 1 test,
· A positive UWSF test at the baseline.
Since the patients in our study had SSc, Sjögren’s
syndrome was classified as defined by the AECG criteria
for secondary SjS [8].
2.1 Histopathological analysis
The same experienced pathologist assessed MSG biopsy
materials. All slides were assessed for surface area,
intensity of lymphocytic infiltration, number of foci, the
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Figure 1. Overview of the methodology used for the study.

presence of any giant focus, lobular and acinar atrophy,
nonspecific sialadenitis, and location and intensity of
fibrosis. Histological demonstration of a focal lymphocytic
sialadenitis, a focus score (inflammatory infiltrate
characterized by the presence of 50 or more lymphocyte)
≥ 1 (grade 3 or 4 in a 4 mm² area of the salivary gland
tissue based on Chisholm and Mason scale) was defined
as diagnostic for SjS [13]. Fibrosis was graded as mild,
moderate and severe.
2.2 Immunohistochemical analysis
In biopsy specimens from MSG, α–SMA expression was
assessed by immunohistochemistry. For this purpose,
sections prepared on poly-L-lysine coated slides were
stained by actin (actin smooth muscle (ASM-1)-alpha
Mouse/Afpur IB; IHP; IF Hu, 25 uq, Quartett). An
experienced pathologist assessed the sections by using a
light microscope. Positive staining of myoepithelial cells
and smooth muscles of vessel walls provided an internal
control for each case. Expression of α–SMA was considered
‘positive’ when findings in stromal region were positive in
nonepithelial areas of tubule-alveolar region.

2.3 Ethics
The Dokuz Eylül University Hospital Ethics board approved
the study with the number of B.30.2.DEU.0.01.00.00/13529.
Every patient who agreed to participate in the study
provided a written informed consent.
2.4 Statistical analysis
The continuous variables were presented as means
and standard deviations and categorical variables were
presented as percentages. A nonparametric Spearman’s
test was used to analyze inter-variable correlations and
the multivariate logistic regression test was used to detect
variables to be used to predict the development of SjS.
A SPSS v.11.0 (SPSS Chicago, İllinois, USA) database
was used to conduct all study analyses. The statistical
significance level was defined as p values less than 0.05.
3. Results
There were 102 patients with SSc [91 (89%) females; mean
age 52.5 ± 12 years] who followed-up in the rheumatology
outpatient clinic. The mean age at the onset of the disease
was 42.3 ± 14.8 years and the mean disease duration was
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10.9 ± 9.8 years. The majority of patients had limited SSc
subtype (LSSc) [85 patients (83%)]. Other subgroups were
diffuse SSc (dSSc) [12 patients (%12)] and sine SSc (sSSc)
[5 patients (5%)].
In our study group the mean ESR was 31.4 ± 18 mm/h
and the mean serum CRP level was 9.1 ± 16.5 mg/L.
Ninety-five patients (93%) tested positive for ANA. The
most common ANA staining pattern was the homogenous
pattern with a frequency of 48%. Other ANA types detected
in the specimens and their distributions were as follows:
centromeric (34%), nucleolar (8%), and granular (5%).
Anti-ENA was positive in 49% of the patients. Anti Scl-70
was positive in 38% of the patients. Anti SS-A antibody
was positive in 13 patients’ antibodies, alone or with
other autoantibodies. Anti SS-B was positive in only one
patient who also tested positive for anti SS-A antibodies
(Table 1). Also 20 patients (20%) had pulmonary arterial
hypertension (PAH) and 35 patients (34%) had interstitial
lung disease (ILD) (Table 2).
A structured questionnaire administered to the
patients revealed that 76 out of 102 (75%) patients had
subjective sicca symptoms [xerophthalmia in 49 (48%)
and xerostomia in 65 (64%)]. The Schirmer 1 test was
positive in 65 patients (64%) and the UWSF was positive
in 36 patients (35%). A MSG biopsy was indicated in 90
patients according to the study protocol. Six out of these
90 patients refused to undergo a biopsy and a total of 84
patients underwent a biopsy (Figure 1).
In histopathologic analysis, fibrotic lesions were
observed in the specimens from 67 patients (80%) while
the focus score was ≥ 1 in 38 (45%) patients (Figure 2). The
rates of patients with mild, moderate and severe fibrosis
were 67%, 24% and 9%, respectively.
Consequently, 36 (35.3%) patients were classified as
having secondary SjS according to the AECG classification
criteria. Twelve patients with secondary SjS had a focus
score of <1 in MSG biopsies.
The SSc patients of whom had secondary SjS, 34 had
LSSc and 2 had sine scleroderma. In patients with SSc and
SjS, none of the patients had dSSc. In patients with diffuse
SSc, histological analysis of biopsy specimens from six
patients revealed glandular fibrosis at variable rates while
one of these specimens exhibited severe fibrosis. Glandular
fibrosis was seen in 6 patients with dSSc (50%) and 61
patients with LSSc (71.8%) (p: 0.18).
Immunohistochemical analyses revealed that only 7
biopsy specimens exhibited a weak staining with α-SMA.
All of these 7 patients had LSSc subtype of SSc (Table 3).
Among specimens positive for α–SMA staining, the focus
score was ≥ 1 in salivary gland specimens from 3 patients
and all of them exhibited glandular fibrosis ranging from
mild to severe in intensity.
The presence of secondary SjS found to be moderately
correlated with age, age at the onset of symptoms and
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Table 1. The clinical and laboratory data of the patients with SSc.
Parameter
Age (years); mean ± SD

52.5 ± 12

Sex, female; n (%)

91 (89%)

SSc subtype
LSSc; n (%)
dSSc; n (%)
sSSc; n (%)

91 (89%)
85 (83%)
12 (12%)
5 (5%)

Disease duration (years); mean ± SD

10.9 ± 9.8

ESR (mm/h); mean ± SD

31.4 ± 18.0

CRP (mg/L); mean ± SD

9.1 ± 16.5

ANA positivity; n (%)

95 (95%)

ANA (centromeric); n (%)

34 (34%)

Anti SS-A positivity; n (%)

13 (13%)

Anti Scl-70 positivity; n (%)

38 (38%)

SSc: systemic sclerosis; dSSc: diffuse form systemic sclerosis;
LSSc: localized form systemic sclerosis; sSSc. sine scleroderma;
ESR: erythrocyte sedimentation rate; CRP: serum C-reactive
protein; ANA: antinuclear antibody. SD: standard deviation.

Table 2. The clinical features and the organ involvements of the
patients with SSc.
Clinical feature
Modified Rodnan score; mean ± SD

10.4 ± 8.4

Interstitial lung disease; n (%)

35 (34%)

Pulmonary arterial hypertension; n (%)

20 (20%)

Digital ulcers n (%)

19 (19%)

Digital gangrenes; n (%)

3 (3%)

VAS score; mean ± SD

4.7 ± 2.3

Functional score; mean ± SD

6.8 ± 7.8

SD: standard deviation; VAS: visual analogue scale.

having positive anti SS-A [correlation coefficient (r) were
r: 0.407 (p < 0.0001); r: 0.343 (p < 0.0001) and r: 0.270
(p: 0.006), respectively] and weakly correlated with the
presence of positive RF [r: 0.216 (p: 0.035)].
In our study group, no associations were found
between the presence of secondary SjS and other clinical
and laboratory parameters including positive ANA, antiScl70 and anticentromere antibodies, having PAH, high
levels of ESR and serum CRP.
In patients with SSc, the factors of age, age at the
onset of symptoms, positive SS-A antibodies, positive
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Figure 2. The findings of histopathologic evaluations of MSG biopsy specimens. MSG:
minor salivary gland; n: number.
Table 3. The clinical features of the patients with SSc who had positive α–SMA in MSG biopsies.
Patient

Focus
score ≥1

Fibrosis

Schirmer (+) UWSF (+)

Lung fibrosis

PAH

ANA
Pattern

Anti-ENA
screen

1.

+

Moderate

+

+

-

-

Centromeric

Negative

2.

+

Serious

+

+

-

NA*

Centromeric

Negative

3.

+

Mild

+

-

+

-

Nucleolar

Negative

4.

-

Serious

+

-

-

+

Nucleolar

Negative

5.

-

Moderate

-

-

+

-

Homogenous

Anti Scl-70

6.

-

Mild

+

+

-

+

Nucleolar

Negative

7.

-

Moderate

+

-

+

-

Nucleolar

Negative

SSc: scleroderma, SjS: Sjögren’s syndrome; α – SMA: alfa-smooth muscle actin; UWSF: unstimulated whole salivary flow; PAH:
pulmonary arterial hypertension; ANA: antinuclear antibody, NA: not available.

RF, having PAH and ILD were evaluated as possible risk
factors for secondary SjS. In univariate logistic regression
analyse, age, age at the onset of symptoms, positive SS-A
were found related with secondary SjS. In multivariate
logistic regression analyse, only two variables were
statistically significant independent predictor factors for
the development of secondary SjS: age and positive SS-A
(Table 4). In this study a significant association was found
between older age and glandular fibrosis in minor salivary
gland specimens (p: 0.034), however no association was
found between the presence of fibrosis and other clinical
and laboratory parameters.
4. Discussion
This study showed, the prevalence of sicca symptoms was
found to be very common among patients with SSc (75%).
Also secondary SjS was detected in nearly one-third of the
patients with SSc (35.3%), especially in the limited subtype
of SSc. The main predictors of having secondary SjS were
detected as anti-SS-A positivity and older age in patients
with SSc. The patients with SSc frequently encountered
with sicca symptoms so these findings were important in
understanding the pathogenesis of this condition.
The association of SSc and SjS has been reported in a
range varying from 1% to 90% in previous studies many of
which were very old. This wide range of prevalence might
depend on heterogeneity of the definitions for the SjS.
More than ten classification criteria sets have composed
for SjS since today. One of the highest prevalence of

Table 4. Results of multivariate logistic regression analyze for
risk factors affecting having SjS in patients with SSc.
Risk factor

P value OR (95% CI)

Age

0.038*

0.109 (1.004–1.033)

Age at the onset of symptoms

0.062

1.020 (0.999–1.043)

Positive SS-A

0.015*

3.211 (1.310–5.980)

secondary SjS has been reported by Alarcon-Segovia et
al., as 90% in patients with SSc [2]. They analyzed all the
objective and subjective tests for SjS, Schirmer 1, Rose
Bengal tests, parotid sialography and scintigraphy, MSG
biopsies, and then accepted patient as secondary SjS if
either of them positive. The prevalence of SSc-associated
SjS was reported as 69% by Spanish investigators [14]. In
this study Coll et al., defined secondary SjS as, two out of
three criteria were prerequisite to define SjS in patients
with SS included xerostomia (based on MSG biopsy
or scintigraphy), xerophthalmia (based on subjective
irritation and burning sensation, the Schirmer 1 and the
Rose Bengal test) and having autoimmune disorders [14].
Cipoletti et al., classified SjS based on the findings from
MSG biopsies, independently from clinical manifestations
and the prevalence of SjS was found to be 17%, which
was lower than those reported from other studies [15].
In another study from Greece, the prevalence of SjS
was found to be 20.5% in 44 patients with SSc [16]. A
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positive MSG biopsy and the presence of xerostomia
(subjective symptoms or reduced parotid salivary flow
rate) or xerophthalmia (a positive Rose Bengal test) were
the prerequisites for a diagnosis of SjS in this study. The
Copenhagen criteria were used to diagnose SjS in a study
conducted in patients with SSc and only one patient was
diagnosed with secondary SjS [17]. There was one study
using the AECG criteria to investigate the prevalence of
SSc-associated SjS before. In this prospective study of
Avouac et al., the prevalence of SjS among patients with
SSc was found to be 14% [4].
In our study the AECG criteria [8] was preferred to
use, which covers both subjective and objective items;
and at least one serological/histopathological item needed
to be classify a patient as having primary SjS. And the
AECG criterion was preferred because it was one the
most commonly used validated criteria set in the studies
of SjS. In our study the prevalence was detected 35.3%
for secondary SjS in patients with SSc. This was a higher
prevalence than the Avouac et al., who used also the AECG
criteria; however, this study did not comply with the 5th
item (UWSF) of this criterion set, as stated by the authors
and this might have contributed to the low SjS prevalence
reported in this study.
The distribution of the different subtypes of the
SSc might also play a role in the variability of the SjS
prevalence rates reported from the studies in the literature.
All patients with SjS in our study had limited cutaneous
form of scleroderma and these data were consistent with
previous data indicating that LSSc might be a risk factor
for the development of SjS [3,4]. In our study although
a statistically significant association was found between
SjS and the limited cutaneous subtype of scleroderma
in correlation analysis (p: 0.024), this result should be
interpreted with caution since none of the patients with
dSSC had SjS. This observation might be the result of
underrepresentation of dSSc (only 12% of the subjects)
in our cohort. The low ratio of dSSc patients in our study
also contributed to our inability to demonstrate any
associations between the development of SjS and different
autoantibodies such as anti-centromere autoantibodies or
anti-scl70 antibodies.
The reasons for the propensity to SjS in patients with
LSSc have remained unknown, as similar with primary
biliary cirrhosis (PBC) that seen more in LSSc. Studies
have pointed out the potential role of Th2 polarization
due to the altered B-cell homeostasis including increased
naive B-cell counts and reduced memory B-cells counts
as well as increased CD4+ and CD30+ T-cell counts and
significantly elevated levels of serum soluble CD30 in
skin biopsy specimens [18,19]. These alterations may
be observed more commonly in patients with LSSc, in
particular when compared to dSSc patients with proven
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clonal expansion of T-cells [4]. This might also explain the
propensity to other autoimmune diseases in patients with
LSSc.
Although the high prevalence of sicca syndrome
in systemic sclerosis is a well-known fact, underlying
etiological factors are not clear. Several studies have
reported that fibrotic changes in salivary glands might
be responsible for these signs and symptoms [2,4]. In our
study, 62 patients had xerostomia and underwent a MSG
biopsy. Having SSC and SjS simultaneously could interpret
these symptoms in half of the patients (31 patients). The
xerostomia of the remaining patients might be explained
by having fibrosis in MSG tissues; the rates of patients with
mild, moderate and severe fibrosis in MSG were 67%, 24%,
and 9%, respectively. These findings were similar with the
data reported that xerostomia in patients with SSc might
be related to glandular fibrosis or secondary to SjS [20]. In
our study older age (p: 0.034) was detected associated with
MSG fibrosis but no associations were found between MSG
fibrosis and clinical signs and symptoms and laboratory
assessments. The focus score was ≥ 1 in 24 patients among
patients having SjS and 21 out of these 24 patients also
had glandular fibrosis. Among 62 patients with SSc who
exhibited xerostomia, a total of 51 had fibrotic changes. So
the fact that fibrosis did not correlate with clinical findings
might be due to its widespread prevalence in patients with
SSc. Our data showed that it is clear that the contribution
of fibrosis cannot be denied in the presence of sicca
symptoms in patients with SSc and also SSC/SjS.
In our cohort 25% of the patients with SSc and
secondary SjS had detected positive for anti SS-A antibody.
The prevalence of anti-SS-A in patients with SSc reported
as similar in some previous studies [16], as well as higher
rates of 53% to 60% also reported by some researchers [21].
In our study there was a correlation between the presence
of anti-SS-A antibodies and co-existence of SjS in patients
with SSc. Also the multivariate regression analysis affirmed
that the presence of anti-SS-A was the sole determinant for
secondary SjS, along with the age. This finding suggested
that anti-SS-A antibody strongly predicts the development
of SjS in patients with SSc.
Likewise the previous studies revealed that the rate of
patients who had positive RF was higher among patients
with SjS/SSc overlap syndrome [22]. Although the
presence of RF was correlated with the development of
secondary SjS (r: 0.216, p: 0.035) in our study, it was not an
independent variable based on regression analysis.
Some previous studies showed an association between
clinical features of SSc and having secondary SjS. For
example the results of three studies [3,4,22] demonstrated
that the presence of SjS in association with SSc might be
protective against SSc-associated pulmonary fibrosis. In
these studies, SjS was more prevalent in a group of patients
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with LSSc subtype. Also the presence of SjS in association
with SSc might be protective against SSc-associated
pulmonary arterial involvement [22]. In our study, the
groups were detected similar in terms of systemic organ
involvements. Also some authors suggested that there was
a distinct SSc patient subgroup that had anticentromere
antibody (ACA) positivity and SjS overlap, with clinical
features as mild SSc phenotype but more frequently seen of
lymphoma [23]. Very recent imaging studies also supported
this entity by showing similarities in ultrasonography of
salivary glands (SGUS) between patients with primary SjS
and patients with ACA positive-LSSc [24]. Our findings
supported this subtype by showing the high prevalence of
SjS in patients with LSSc. With this growing observational
data, a distinct clinical syndrome might be defined in near
future including the patients with LSSc and SjS overlap.
The main characteristic of the SSc pathogenesis is
pathological fibrosis; excessive deposition of ECM induced
by activated fibroblasts. The cells that play a major role
in fibrogenesis were increased mesenchymal cells, which
had ability of differentiation between myofibroblasts,
fibroblasts, and contractile smooth muscle cells [25].
During the fibrotic process, activated mesenchymal
cells in tissue promote ECM. Myofibroblasts that are
specialized cells that synthesize collagens; tissue inhibitors
of metalloproteinases and other ECM components are both
the main source of TGF-β and also transdifferentiate from
fibroblasts in response to TGF-β. Myofibroblasts express a
cytoskeleton protein, α-SMA [26]. Other than the dermis,
the expression of TGF-β, α-SMA and other cytokines was
also demonstrated by immunohistochemistry in biopsy
specimens from the stomach walls of patients with SSc [27].
There is very limited information about the pathogenesis
of fibrotic lesions of pulmonary tissue and others in SSc.
Therefore, in this study, we also investigated whether or
not myofibroblastic transformation, which was known to
contribute to skin lesions of SSc, had a role in the occurrence
of sicca symptoms. However, a weak immunohistochemical
staining with α-SMA was detected in specimens from 7
patients. Fibrotic changes were detected in all of these
specimens and the focus score was ≥ 1 in specimens from

3 patients. However, these results suggest that the α-SMA
expression and thereby myofibroblasts might not play a role
in the occurrence of sicca symptoms or in the development
of SjS. Similar as our study, measurement of α-SMA in
other tissues such as skeletal muscle was not associated
with for fibrosis (for familial muscular dystrophies) [28].
But Sisto et al. suggested opposite findings about α-SMA
in a study comparing patients with pSS and healthy people.
They suggested disappearing of α-SMA might be one of the
disturbance associated with disease pathology [29]. The
weak expression of α-SMA might contribute to the loss
of myoepithelial cells and mechanical support concluded
with the reduction of salivary gland flow and xerostomia.
As a limitation, in our study there was not a group of
healthy subjects or primary SjS patients for evaluating
the measurement of α-SMA. A further study including a
control group for evaluating α-SMA is needed to confirm
the interpretation of histopathologic findings.
In conclusion, this study showed the prevalence of sicca
symptoms was found to be very common, and secondary
SjS was seen in nearly one-third of patients with SSc. These
findings suggest that the association between SSc and SjS
was not coincidental and unknown common factors might
play a role in the pathogenesis. Especially the limited
subtype of patients with SSc was found to be associated with
SjS. This study showed that it is clear that the contribution of
fibrosis cannot be denied in the presence of sicca symptoms
in SSc patients with or without secondary SjS. But further
investigation into the α-SMA needed to define its role in
the mechanisms of salivary gland dysfunction.
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